Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?

Bequignon E, Dhommée C, Angely C, Thomas L, Bottier M, Escudier E, Isabey D, Coste A, Louis B, Papon JF, Gouilleux-Gruart V.

Int J Mol Sci. 2019 Mar 19;20(6). pii: E1379. doi: 10.3390/ijms20061379.

2.

A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.

Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnière M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlegrin A, Poul MA.

MAbs. 2019 Apr;11(3):593-605. doi: 10.1080/19420862.2018.1564510. Epub 2019 Feb 18.

3.

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment.

Castaneda DC, Dhommée C, Baranek T, Dalloneau E, Lajoie L, Valayer A, Arnoult C, Demattéi MV, Fouquenet D, Parent C, Heuzé-Vourc'h N, Gouilleux-Gruart V.

Front Immunol. 2018 Sep 28;9:2259. doi: 10.3389/fimmu.2018.02259. eCollection 2018.

4.

T lymphocyte immunophenotyping in bronchoalveolar lavage on AQUIOS CL® cytometer.

Humeau C, Darrouzain F, Gouilleux-Gruart V.

J Immunol Methods. 2018 Oct;461:91-99. doi: 10.1016/j.jim.2018.06.022. Epub 2018 Jul 3.

PMID:
30158078
5.

Tocilizumab Contributes to the Inflammatory Status of Mature Dendritic Cells through Interleukin-6 Receptor Subunits Modulation.

Meley D, Héraud A, Gouilleux-Gruart V, Ivanes F, Velge-Roussel F.

Front Immunol. 2017 Aug 16;8:926. doi: 10.3389/fimmu.2017.00926. eCollection 2017.

6.

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.

Arnoult C, Brachet G, Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, Paintaud G, Heuzé-Vourc'h N, Watier H, Gouilleux-Gruart V.

J Immunol. 2017 Jul 15;199(2):418-424. doi: 10.4049/jimmunol.1601246. Epub 2017 Jun 5.

7.

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.

Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Mélet J, Paintaud G, Ternant D.

Br J Clin Pharmacol. 2017 Aug;83(8):1773-1781. doi: 10.1111/bcp.13270. Epub 2017 Apr 12.

8.

STAT5A/5B-specific expansion and transformation of hematopoietic stem cells.

Ghanem S, Friedbichler K, Boudot C, Bourgeais J, Gouilleux-Gruart V, Régnier A, Herault O, Moriggl R, Gouilleux F.

Blood Cancer J. 2017 Jan 6;7(1):e514. doi: 10.1038/bcj.2016.124. No abstract available.

9.

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuaillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G, Apparailly F.

Haematologica. 2017 Apr;102(4):746-754. doi: 10.3324/haematol.2016.153189. Epub 2017 Jan 25.

10.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
11.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Clin Pharmacokinet. 2017 Jun;56(6):635-647. doi: 10.1007/s40262-016-0470-8.

PMID:
27783363
12.

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.

Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D.

Clin Pharmacokinet. 2016 Nov;55(11):1381-1394.

PMID:
27312193
13.

Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.

Bourgeais J, Ishac N, Medrzycki M, Brachet-Botineau M, Desbourdes L, Gouilleux-Gruart V, Pecnard E, Rouleux-Bonnin F, Gyan E, Domenech J, Mazurier F, Moriggl R, Bunting KD, Herault O, Gouilleux F.

Oncotarget. 2017 Jun 27;8(26):41876-41889. doi: 10.18632/oncotarget.11480.

14.

Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action.

Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-Gruart V, Poupon A, Watier H.

Mol Immunol. 2016 Sep;77:126-31. doi: 10.1016/j.molimm.2016.07.016. Epub 2016 Aug 5.

PMID:
27497837
15.

Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis.

Dalloneau E, Baroukh N, Mavridis K, Maillet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, Cadena Castaneda DC, Dhommée C, Arnoult C, Scorilas A, Gouilleux-Gruart V, Heuzé-Vourc'h N.

Oncotarget. 2016 Aug 23;7(34):54415-54429. doi: 10.18632/oncotarget.10074.

16.

Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.

Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommée C, Viaud-Massuard MC, Heuze-Vourc'h N, Joubert N, Pugnière M, Gouilleux-Gruart V.

Mol Pharm. 2016 Apr 4;13(4):1405-12. doi: 10.1021/acs.molpharmaceut.6b00082. Epub 2016 Mar 1.

PMID:
26900766
17.

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.

Gagez AL, Tuaillon E, Cezar R, Dartigeas C, Mahé B, Letestu R, Maisonneuve H, Gouilleux-Gruart V, Bollore K, Ferrant E, Aurran T, Feugier P, Leprêtre S, Cartron G.

Blood Cancer J. 2016 Jan 22;6:e389. doi: 10.1038/bcj.2015.115. No abstract available.

18.

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Diéras V, Jimenez M, Paintaud G, Ternant D.

Br J Clin Pharmacol. 2016 May;81(5):941-8. doi: 10.1111/bcp.12875. Epub 2016 Mar 7.

19.

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.

Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V.

J Immunol. 2016 Jan 15;196(2):607-13. doi: 10.4049/jimmunol.1501780. Epub 2015 Dec 18.

20.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

PMID:
26615857
21.

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H.

MAbs. 2015;7(6):1205-11. doi: 10.1080/19420862.2015.1086049. Epub 2015 Sep 4.

22.

Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance.

Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S.

Sci Transl Med. 2015 Feb 18;7(275):275ra21. doi: 10.1126/scitranslmed.aaa1957.

PMID:
25696000
23.

Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2.

Rollin J, Pouplard C, Sung HC, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y.

Blood. 2015 Apr 9;125(15):2397-404. doi: 10.1182/blood-2014-09-594515. Epub 2015 Feb 13.

24.

The neonatal Fc receptor does not modulate hepatitis C virus neutralization.

Morel A, Passot C, Arnoult C, Dumans A, Beaumont E, Gouilleux-Gruart V, Roingeard P, Blanchard E.

J Gen Virol. 2015 May;96(Pt 5):1062-6. doi: 10.1099/vir.0.000060. Epub 2015 Jan 22.

PMID:
25614590
25.

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.

Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G.

Clin Pharmacokinet. 2015 May;54(5):551-62. doi: 10.1007/s40262-014-0225-3.

PMID:
25516415
26.

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.

Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc'h N.

J Control Release. 2014 Dec 28;196:344-54. doi: 10.1016/j.jconrel.2014.10.003. Epub 2014 Oct 17.

PMID:
25451545
27.

Oxidative metabolism in cancer: A STAT affair?

Bourgeais J, Gouilleux-Gruart V, Gouilleux F.

JAKSTAT. 2013 Oct 1;2(4):e25764. doi: 10.4161/jkst.25764. Epub 2013 Aug 12. Review.

28.

ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.

Lajoie L, Congy-Jolivet N, Bolzec A, Gouilleux-Gruart V, Sicard E, Sung HC, Peiretti F, Moreau T, Vié H, Clémenceau B, Thibault G.

J Immunol. 2014 Jan 15;192(2):741-51. doi: 10.4049/jimmunol.1301024. Epub 2013 Dec 13.

29.

Primary immune deficiencies: practical questions.

Gouilleux-Gruart V, Schleinitz N, Fischer A.

Curr Opin Allergy Clin Immunol. 2013 Jul;13 Suppl 2:S67-78. doi: 10.1097/01.all.0000433133.93564.c7. Review. No abstract available.

PMID:
23873316
30.

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.

Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, Boisdron-Celle M, Gamelin E, Watier H, Paintaud G, Gouilleux-Gruart V.

MAbs. 2013 Jul-Aug;5(4):614-9. doi: 10.4161/mabs.24815. Epub 2013 Apr 25.

31.

Reliability of the nanopheres-DNA immunization technology to produce polyclonal antibodies directed against human neogenic proteins.

Arnaoty A, Gouilleux-Gruart V, Casteret S, Pitard B, Bigot Y, Lecomte T.

Mol Genet Genomics. 2013 Aug;288(7-8):347-63. doi: 10.1007/s00438-013-0754-8. Epub 2013 Jun 7.

PMID:
23743652
32.

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.

Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, Patel S, Boutboul D, Marson MN, Gérard L, Lee M, Watier H, Oksenhendler E; DEFI study group.

Clin Exp Immunol. 2013 Feb;171(2):186-94. doi: 10.1111/cei.12002.

33.

FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.

Lejeune J, Piègu B, Gouilleux-Gruart V, Ohresser M, Watier H, Thibault G.

MAbs. 2012 Nov-Dec;4(6):784-7. doi: 10.4161/mabs.22287. Epub 2012 Oct 2.

34.

Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.

Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y.

Blood. 2012 Aug 9;120(6):1309-16. doi: 10.1182/blood-2012-04-424044. Epub 2012 Jun 7.

35.

Evidence for a protective role of the STAT5 transcription factor against oxidative stress in human leukemic pre-B cells.

Cholez E, Debuysscher V, Bourgeais J, Boudot C, Leprince J, Tron F, Brassart B, Regnier A, Bissac E, Pecnard E, Gouilleux F, Lassoued K, Gouilleux-Gruart V.

Leukemia. 2012 Nov;26(11):2390-7. doi: 10.1038/leu.2012.112. Epub 2012 Apr 23.

PMID:
22522791
36.

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.

Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.

Clin Cancer Res. 2011 Oct 1;17(19):6329-37. doi: 10.1158/1078-0432.CCR-11-1081. Epub 2011 Sep 27.

37.

Regulation of IGF-1-dependent cyclin D1 and E expression by hEag1 channels in MCF-7 cells: the critical role of hEag1 channels in G1 phase progression.

Borowiec AS, Hague F, Gouilleux-Gruart V, Lassoued K, Ouadid-Ahidouch H.

Biochim Biophys Acta. 2011 May;1813(5):723-30. doi: 10.1016/j.bbamcr.2011.01.025. Epub 2011 Feb 16.

38.

The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction.

Dhennin-Duthille I, Nyga R, Yahiaoui S, Gouilleux-Gruart V, Régnier A, Lassoued K, Gouilleux F.

J Biol Chem. 2011 Feb 18;286(7):5034-42. doi: 10.1074/jbc.M110.155903. Epub 2010 Nov 24.

39.

STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.

Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, Perrot C, Vieillard V, Dartigues P, Gaulard P, Agbalika F, Douay L, Lassoued K, Gorin NC.

Leukemia. 2009 Sep;23(9):1667-78. doi: 10.1038/leu.2009.91. Epub 2009 May 7.

40.

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lannerée S, Kenner L, Kerenyi M, Yahiaoui S, Gouilleux-Gruart V, Gondry J, Bénit L, Dusanter-Fourt I, Lassoued K, Valent P, Moriggl R, Gouilleux F.

Blood. 2008 Sep 15;112(6):2463-73. doi: 10.1182/blood-2007-09-115477. Epub 2008 Jun 25. Erratum in: Blood. 2009 Aug 20;114(8):1720.

41.

Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.

Guillaume N, Gouilleux-Gruart V, Claisse JF, Troussard X, Lepelley P, Damaj G, Royer B, Garidi R, Lefrere JJ.

Leuk Lymphoma. 2007 Aug;48(8):1556-60.

PMID:
17701587
42.

Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.

Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, Gouilleux F.

Blood. 2007 Feb 15;109(4):1678-86. Epub 2006 Oct 12.

43.

Polyclonal IgG4 hypergammaglobulinemia associated with plasmacytic lymphadenopathy, anemia and nephropathy.

Boulanger E, Fuentes V, Meignin V, Mougenot B, Labaume S, Gouilleux-Gruart V, Cogné M, Aucouturier P, Clauvel JP, Ronco P, Lassoued K.

Ann Hematol. 2006 Dec;85(12):833-40. Epub 2006 Jul 27.

PMID:
16871390
44.

ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.

Guillaume N, Alleaume C, Munfus D, Capiod JC, Touati G, Pautard B, Desablens B, Lefrère JJ, Gouilleux F, Lassoued K, Gouilleux-Gruart V.

Haematologica. 2005 Jul;90(7):899-905.

45.

Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter.

Nyga R, Pecquet C, Harir N, Gu H, Dhennin-Duthille I, Régnier A, Gouilleux-Gruart V, Lassoued K, Gouilleux F.

Biochem J. 2005 Aug 15;390(Pt 1):359-66.

46.

Autoimmune cytopenias associated with autoantibodies to nuclear envelope polypeptides.

Coppo P, Clauvel JP, Bengoufa D, Fuentes V, Gouilleux-Gruart V, Courvalin JC, Lassoued K.

Am J Hematol. 2004 Nov;77(3):241-9.

47.

[Prevalence of celiac disease markers in a French cohort of children and adolescents with type 1 diabete mellitus].

Beltran S, Bony-Trifunovic H, Gouilleux-Gruart V, Djeddi D, Dadamessi I, Dupas JL, Boudailliez B.

Ann Endocrinol (Paris). 2004 Apr;65(2):131-5. French.

PMID:
15247873
48.

The inhibition of cell spreading on a cellulose substrate (cuprophan) induces an apoptotic process via a mitochondria-dependent pathway.

Gekas J, Hindié M, Faucheux N, Lanvin O, Mazière C, Fuentès V, Gouilleux-Gruart V, David B, Mazière JC, Lassoued K, Nagel MD.

FEBS Lett. 2004 Apr 9;563(1-3):103-7.

49.

Interleukin-7 induces apoptosis of 697 pre-B cells expressing dominant-negative forms of STAT5: evidence for caspase-dependent and -independent mechanisms.

Lanvin O, Gouilleux F, Mullié C, Mazière C, Fuentes V, Bissac E, Dantin F, Mazière JC, Régnier A, Lassoued K, Gouilleux-Gruart V.

Oncogene. 2004 Apr 15;23(17):3040-7.

PMID:
15048088
50.

Differential effect of dexamethasone on cell death and STAT5 activation during in vitro eosinopoiesis.

Debierre-Grockiego F, Fuentes V, Prin L, Gouilleux F, Gouilleux-Gruart V.

Br J Haematol. 2003 Dec;123(5):933-41.

PMID:
14632786

Supplemental Content

Loading ...
Support Center